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Recent advances in embryonic stem cell (ESC) derivation and genome editing offer efficient platforms for
genetic screening. In this issue, Li et al. and Leeb et al., respectively, expand such applications by generating
haploid rat ESCs for screening,mutagenesis, andCRISPR-Cas-mediated gene targeting and by developing a
forward genetic screen for interrogating haploid mESCs.In the past three decades, mammalian
genetics and stem cell biology have
been developed in close synergy with
each other. Continuous technological
progress in mammalian genetics largely
depends on the availability of mouse em-
bryonic stem cells (ESCs). Many reverse
genetic approaches have taken advan-
tage of the pluripotency of genetically
engineered mouse ESCs to produce
animals with germline-transmitted muta-
tions. However, in forward genetic
screens, researchers have often em-
ployed the self-renewal property of
cultured mouse ESCs to streamline
mutagenesis and clone archival re-
sources, and in comparison to whole-
animal approaches, using mouse ESCs
thus offers significant flexibility and
cost reduction. If ESC-based genetic
approaches are to be extended to a
broader range of animal species and
applications, two major obstacles should
be addressed: low or variable rates of
germline transmission in different strains
and species and difficulties in pheno-
type-driven screening of recessive ge-
netic traits that are masked by the diploid
nature of mammalian genomes. In this
issue of Cell Stem Cell, Li et al. (2014)
(Figure 1A) and Leeb et al. (2014)
(Figure 1B) demonstrate practical solu-
tions to these problems. It is noteworthy
that both studies are based on haploid
ESC technology.
In mammals, haploidy is normally
restricted to the post-meiotic stages of
germ cells and represents the end point
of cell proliferation, which means that
physiological haploidy is incompatible
with self-renewal. The recent advent of
haploid mouse ESC technologies has
drastically changed this situation. Theoriginal versions of haploid ESC lines
(Elling et al., 2011; Leeb and Wutz, 2011)
were generated by parthenogenetic
activation of unfertilized mouse oocytes
with chemicals such as strontium salt or
ethanol (Figure 1B). These haploid mouse
ESCs contain only the maternal set of
chromosomes and show pluripotency
as well as self-renewal capabilities.
Because these cells show an inherent
tendency toward spontaneous diploidi-
zation in culture, periodic purification by
flow sorting is necessary if cultures con-
taining a large majority of haploid cells
are to be maintained. Although haploid
ESCs appear to be inevitably diploidized
upon differentiation, they can give rise to
a wide range of cell types, including
germ cells in chimeric mice, both in vitro
and in vivo. Androgenetic haploid mouse
ESC lines containing only the paternal
chromosomes have also been generated
by removal of the maternal pronucleus
from zygotes and by introduction of
sperm into enucleated oocytes (Li et al.,
2012; Yang et al., 2012). Thus, pluripo-
tency, self-renewal, and haploidy can be
incorporated together in a single cell line.
Li et al. (2014) have successfully
extended the zygote-based strategy of
androgenetic haploid ESC derivation to
the rat, which in many ways is more
advantageous than the mouse as an
animal model of human physiology,
behavior, and disease. Only a few years
have passed since the first authentic rat
ESCs were isolated, and rat genetic tools
have still lagged behind those available
for the mouse. Li et al. (2014) found that
their newly established rat androgenetic
haploid ESCs (RahESCs) are pluripotent
and self-renewable and can serve as a
‘‘sperm-like’’ genetic tool (Figure 1A). InCell Stem Celltheir study, Li et al. engineered the Ra-
hESCs by inserting a red fluorescent
protein (RFP) marker transgene and tar-
geting deletion of the Scn4b gene that
has been implicated in human long-QT
syndrome. Strikingly, intracytoplasmic
injection of the RahESCs into metaphase
oocytes, assisted by chemical activation,
led to production of fertile rats that inherit
the RFP transgene and Scn4b deletion.
This procedure is termed intracyto-
plasmic RahESC injection (ICAI) and is
reminiscent of the widely used intracyto-
plasmic sperm injection (ICSI) method,
which demonstrates the use of renewable
‘‘sperm-like’’ cells for transgenic rat
production. Moreover, RahESCs provide
a desired platform for recessive genetic
screening, as exemplified by random
insertion of gene trap elements into the
haploid genome via piggyBac (PB) trans-
posons. RahESCs also demonstrated
potential multiple-site-specific targeting
of three Tet family geneswhen the authors
used the CRISPR-Cas9 system. Both
of these procedures ultimately gave
rise to homozygous mutants through
diploidization.
In the second study, Leeb et al. (2014)
clearly demonstrate the power of reces-
sive genetic screening in haploid ESCs
(Figure 1B). The self-renewal property of
mouse haploid ESCs allows a random
mutagenesis screen to identify factors
that promote exit from the self-renewal
state itself. A haploid reporter ESC line
expressing destabilized GFP under the
control of the endogenous promoter for
Rex1, a known marker of pluripotency,
has been used to monitor the mainte-
nance of self-renewal. The ESCs were
mutagenized by random insertion of PB-
based gene-trap transposons and then14, March 6, 2014 ª2014 Elsevier Inc. 265
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Figure 1. Haploid Embryonic Stem Cell System as a Versatile Genetic Tool in Rodents
(A) Intracytoplasmic rat androgenetic haploid ESC injection (ICAI) contributes to production of both transgenic (RFP+) and knockout (Scn4b+/) mutant rats.
(B) Gene-trap mutagenesis of mouse parthenogenetic haploid ESCs allows loss-of-function genetic screening to identify genes (Zfp706 and Pum1) that promote
exit from the self-renewal state. Blue and red rectangles represent the paternal and maternal sets of haploid chromosomes, respectively. Yellow stars represent
mutations. SpB indicates the second polar body.
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Previewscultured in differentiation-permissive
conditions. After repetition of the differ-
entiation induction, fractions of GFP-
retaining cells were processed for positive
selection in the defined 2i/LIF medium, in
which only self-renewing stem cells can
grow. At the end, the candidate gene-
trap mutations responsible for the per-
sistent self-renewal were collectively
recovered by deep sequencing. These
results provided a proof-of-principle of
this elegant approach by isolating known
differentiation inducers, including multiple
components of the Fgf/Erk and GSK3/
Tcf3 signaling pathways. Moreover, the
authors identified and validated factors
not previously implicated in pluripotent
cell biology. These factors included the
small zinc finger protein Zfp706, which
represses the pluripotency factor Klf4,
and the RNA binding protein Pum, which
downregulates naive pluripotency circuit
genes in a post-transcriptional manner.
Historically, loss-of-function genetic
screening has been the most advanced266 Cell Stem Cell 14, March 6, 2014 ª2014in yeast because of the availability of effi-
cient methodologies. Therefore, ‘‘yeast
envy’’ has motivated mammalian geneti-
cists to develop tools such as the engi-
neered diploid Blm mutant ESC line with
inducible loss-of-heterozygosity (Horie
et al., 2011) and the above-mentioned
haploid ESC lines. Most recently, three
independent groups have constructed
genome-scale single-guide RNA (sgRNA)
libraries of the CRISPR-Cas9 system for
human (Shalem et al., 2014: Wang et al.,
2014) and mouse (Koike-Yusa et al.,
2013) cells. Lentiviral delivery of a library
leads to stable integration and expression
of sgRNA, mostly resulting in iterative
biallelic cleavage of target sites in diploid
cells until both alleles lose the target
sequences by misrepair. Because the
integrated sgRNA sequences serve
as DNA barcodes, this type of mutagen-
esis allows recessive loss-of-function
screening for both positive and negative
selection. The majority of mutations
generated by CRISPR-Cas9-mediatedElsevier Inc.cleavage are relatively small deletions
(<20 bp) and could be insufficient to affect
the function of long noncoding genes and
other functional elements. Therefore,
CRISPR-Cas9 and other mutagenesis
systems, including gene trapping in
haploid cells, are mutually supportive.
The next goal would be to discover two
or more genetic components that are
codependent on each other, which would
correspond to the ‘‘synthetic lethal’’
screening approach that is well devel-
oped in yeast. Nevertheless, with a variety
of emerging genetic tools, mammalian
geneticists are now overcoming their
‘‘yeast envy.’’REFERENCES
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The limited supply and expansion capacity of primary human hepatocytes presents major challenges for
pharmaceutical applications and development of cell-based therapies for liver diseases. Now in Cell Stem
Cell, two papers demonstrate efficient direct reprogramming of human fibroblasts into induced hepatocytes,
which exhibit metabolic properties similar to primary hepatocytes.The liver is a unique organ that performs
a broad spectrum of functions. It stores
reserves of iron, vitamins, and minerals
and detoxifies alcohol, drugs, and other
chemicals that accumulate in the blood-
stream. The liver also produces bile, albu-
min, and blood-clotting factors. Finally,
the liver performs an essential metabolic
activity by storing glycogen. These tasks
aremanaged by one cell type, the hepato-
cyte, which constitutes the main cellular
unit of the liver. Genetic disorders or in-
juries that prevent the liver from carrying
out these essential activities result in life-
threatening diagnosis and end-stage liver
diseases that require organ transplanta-
tion. Thus, generating large quantities of
hepatocytes asanalternative to liver trans-
plants is a major objective for drug devel-
opment and regenerative medicine. How-
ever, freshly isolated hepatocytes come
in limited supply, often from donated or-
gans that are of poor quality, and are
impossible to expand in large quantities
in vitro. Therefore, deriving hepatocytes
from stem cell populations such as human
pluripotent stem cells (hPSCs) presents anattractive alternative to primary cells. Now
in Cell Stem Cell, two studies, from the
groups of Lijian Hui and Hongkui Deng,
demonstrate an additional approach by
directly reprogrammingfibroblasts intohu-
man induced hepatocytes (hiHeps) (Du
et al., 2014; Huang et al., 2014).
hPSCs have been used advantageously
to produce hepatocytes for disease
modeling (Rashid et al., 2010) and for
developmental studies. However, genera-
tion of cells displaying all the functional
characteristics of mature hepatocytes
has been proven difficult. Indeed, hPSC-
derived hepatocytes uniformly express
fetal markers such as AFP and lack key
metabolic activity associated with adult
cells such as cytochromep450, especially
CyP3A4. Importantly, recent improve-
ments involving 3D cultures (Ogawa
et al., 2013), small molecule screens
(Shanet al., 2013), andalso in vivomatura-
tion with coculture of endothelial cells
(Takebe et al., 2013) have resulted
in important functional improvements,
including the expression of inducible
CyP3A4 and diminished AFP expression.The development of robust pluripotent
stem cell differentiation protocols has
been impaired by the lack of knowledge
concerning the mechanisms that regulate
the functional maturation of the human
liver after birth. Direct reprogramming ap-
proaches could bypass this last limitation
by avoiding the need to mimic a complex
path of development in vitro. Accordingly,
previous reports have shown that over-
expression of Gata4/HNF1alpha/Foxa3
or HNF4a/FoxA1/FoxA2/FoxA3 in mouse
embryonic fibroblasts, following genetic
ablation of p19, enables the production
of induced hepatocyte-like cells (iHep)
(Huang et al., 2011; Sekiya and Suzuki,
2011). These cells can be expanded
in vitro while displaying a limited meta-
bolic activity, and they retain the capacity
to colonize the failing liver of mice lacking
fumarylacetoacetate hydrolase (Fah/),
a common animal model of liver failure
(Azuma et al., 2007).
The two reportspublished in this issueof
Cell StemCell have successfully extended
this approach to human fetal cells. Huang
et al. (2014) report that overexpression of14, March 6, 2014 ª2014 Elsevier Inc. 267
